2610003J06Rik Activators
When a compound successfully activates the promoter, it induces the expression of the reporter gene, leading to an observable signal. The intensity of this signal correlates with the level of promoter activation and, by proxy, the compound's efficacy as an activator. Compounds that cause a significant enhancement of the reporter signal are then earmarked for more detailed evaluation. The screening process is critical for isolating chemical entities that can effectively modulate gene expression, providing a starting point for further characterization. Following the initial HTS phase, putative 2610003J06Rik Activators undergo a series of validation tests to confirm their gene-activating properties. Quantitative polymerase chain reaction (qPCR) is one of the main techniques used in this stage. It quantifies the mRNA levels of the 2610003J06Rik gene after compound interaction, with an increase in mRNA signifying that the compound can upregulate gene expression at the transcriptional level.
Complementing qPCR, Western blot analysis is conducted to determine whether the observed increase in mRNA levels translates into an increase in the protein encoded by the gene. This technique involves separating proteins by gel electrophoresis, transferring them to a membrane, and then probing with antibodies specific to the target protein. These validation steps-qPCR and Western blot-are indispensable in the characterization process, as they collectively ensure that a chemical compound not only increases the transcription of the 2610003J06Rik gene but also leads to a corresponding increase in protein synthesis. This multi-tiered approach ensures that a compound's role as an activator is thoroughly substantiated by evidence across different levels of gene expression regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, leading to increased cAMP and cGMP levels. This potentiates PKA and PKG pathways, potentially enhancing the activity of 2610003J06Rik through phosphorylation events. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator which could enhance 2610003J06Rik activity by activating protein kinase C, which may then influence signaling pathways or structural elements associated with 2610003J06Rik function. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, potentially enhancing the activity of 2610003J06Rik through calcium-dependent signaling pathways that interact with or modify the protein's function. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, similarly to A23187, raising intracellular calcium and activating calcium-dependent kinases, which could lead to the activation of 2610003J06Rik. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit certain types of protein kinases, potentially altering signaling pathways to favor the activation of 2610003J06Rik by reducing competitive or negative regulatory signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which can modulate the PI3K/Akt pathway, potentially relieving inhibitory control on pathways that 2610003J06Rik is a part of, thereby enhancing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which can shift the balance of cellular signaling to pathways that indirectly enhance the activity of 2610003J06Rik, by inhibiting competing stress response pathways. | ||||||
Spermine | 71-44-3 | sc-212953A sc-212953 sc-212953B sc-212953C | 1 g 5 g 25 g 100 g | $61.00 $196.00 $277.00 $901.00 | 1 | |
Spermine is a polyamine that can modulate ion channel function and may influence signaling pathways that regulate or interact with 2610003J06Rik, leading to its enhanced activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, particularly PDE5, leading to increased cGMP levels, which could enhance the activity of 2610003J06Rik through cGMP-dependent protein kinase activation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor, which can lead to changes in cytoskeletal dynamics and cell motility pathways, potentially enhancing the activity of 2610003J06Rik if it's involved in these processes. | ||||||